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Abstract: Background 
With rapid advancement in the genomics of oesophagogastric (OG) cancer 
and raised expectations in clinical outcomes from patients and clinicians 
alike there is a clear need to determine the current research priorities 
in OG cancer surgery. The aim of our study was to use a modified Delphi 
process to determine the research priorities among OG cancer surgeons in 
the United Kingdom. 
 
Methods 
Delphi methodology may be utilised to develop consensus opinion amongst a 
group of experts. Members of the Association of Upper Gastrointestinal 
Surgeons of Great Britain and Ireland were invited to submit individual 
research questions via an online survey (phase I). Two rounds of 
prioritisation by multidisciplinary expert healthcare professionals 
(phase II and III) were completed to determine a final list of high 
priority research questions. All questions submitted and subsequently 
ranked were analysed on an anonymised basis. 
 
Results 
In total, 427 questions were submitted in phase I and 75 with an OG 
cancer focus were taken forward for prioritisation in phase II. Phase III 
produced a final list of 12 high priority questions with an emphasis on 




A modified Delphi process produced a list of 12 high priority research 
questions in OG cancer surgery. Future studies and awards from funding 
bodies should reflect this consensus list of prioritised questions in the 
interest of improving patient care and encouraging collaborative research 
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Highlights 
 We have produced a list of future research priorities for malignant OG surgery 
by undertaking a Delphi process incorporating members of the OG MDT 
 There is a particular emphasis on the future development of personalised 
therapies in OG cancer surgery 
 Other research priorities identified include; prehabilitation, early detection, 










With rapid advancement in the genomics of oesophagogastric (OG) cancer and raised 
expectations in clinical outcomes from patients and clinicians alike there is a clear need to 
determine the current research priorities in OG cancer surgery. The aim of our study was to 
use a modified Delphi process to determine the research priorities among OG cancer 
surgeons in the United Kingdom. 
 
Methods 
Delphi methodology may be utilised to develop consensus opinion amongst a group of 
experts. Members of the Association of Upper Gastrointestinal Surgeons of Great Britain 
and Ireland were invited to submit individual research questions via an online survey (phase 
I). Two rounds of prioritisation by multidisciplinary expert healthcare professionals (phase II 
and III) were completed to determine a final list of high priority research questions. All 
questions submitted and subsequently ranked were analysed on an anonymised basis. 
 
Results 
In total, 427 questions were submitted in phase I and 75 with an OG cancer focus were 
taken forward for prioritisation in phase II. Phase III produced a final list of 12 high priority 
questions with an emphasis on tailored or personalised treatment strategies in OG cancer 
surgery. 
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Conclusion 
A modified Delphi process produced a list of 12 high priority research questions in OG 
cancer surgery. Future studies and awards from funding bodies should reflect this consensus 
list of prioritised questions in the interest of improving patient care and encouraging 
collaborative research across multiple centres. 
 
Keywords 
Delphi process, oesophagogastric cancer, surgery, research priorities 
Introduction 
 
Oesophagogastric (OG) cancer is a collective term used to describe cancers of the 
oesophagus and stomach. Worldwide, oesophageal cancer is the 8th most common cancer 
and was responsible for 5% of all cancer deaths in 2012. Gastric cancer was responsible for 
9% of worldwide cancer deaths in 2012 (1). Overall 5-year survival for OG cancer is in the 
region of 15% and is dependent upon tumour stage, subtype, comorbidities and patient 
performance status (2, 3). In those who undergo either surgery or endoscopic treatment for 
early stage oesophageal adenocarcinoma the anticipated 5-year survival is 65% (4). The 
management of OG cancer patients encompasses a multidisciplinary approach to patient 
care. Treatment modalities may be curative or palliative, with chemotherapy, radiotherapy 
and surgery used in combination or independently in the majority of fit patients. However, 
the evidence base for treatment decisions is limited and often conflicting.  For example, in 
the curative setting neoadjuvant treatment demonstrates a survival advantage (5-8), but the 
choice between chemotherapy and chemoradiotherapy is determined largely by local 
provision and clinician choice.  Unfortunately, less than 20% pf patients will derive benefit 
from any form of pre-operative treatment, possibly at the expense of harm to those whose 
surgery is delayed (9).  Similar unanswered questions exist in the setting of advanced 
disease and cancer recurrence.  Recent international efforts to determine the genomic and 
molecular landscape of OG cancer are leading to potential new patient stratification and 
treatment options that need to be applied and evaluated in a responsible and scientifically 
robust manner for patient benefit (10-14).  In this context a clear consensus about the 
research priorities for OG cancer is required.   
 
A modified Delphi process can be used to develop a list of priorities by consensus from a 
group of experts. This has been successfully used in colorectal surgery (15), orthopaedics 
(16) plastic surgery (17) and hepato-pancreato-biliary surgery (18) and bariatric surgery (19). 
This approach in determining research priorities improves efficiency and adds greater value 
to those who fund OG cancer research (20). To our knowledge no attempt has previously 
been made to determine the future research priorities in OG cancer surgery. However, 
Delphi methods have been used to produce core information and outcome sets for patients 
undergoing oesophageal cancer surgery (21), the management of Barrett’s dysplasia (22) 
and gastric cancer prevention (23). The aim of our study, was to undertake a modified 




Methods and Materials 
 
A three-phased modified Delphi process was undertaken (Figure 1). This included two 
distinct phases of prioritisation by expert multidisciplinary stakeholders utilising established 
methodology previously described for a number of clinical projects (15, 24, 25). 
Stakeholders were asked to submit questions and, thereafter, prioritise their responses 
based upon their own perceived clinical need. During the prioritisation phases (II and III), 
only complete submissions where all questions were ranked were included in the analysis. 
 
Phase I 
Experts were recruited from the Association of Upper GI Surgeons of Great Britain and 
Ireland (AUGIS) membership, which includes medical professionals and members of the 
wider multidisciplinary team such as research nurses, dieticians and cancer specialist nurses. 
Members were invited by email to submit research questions across the entire spectrum of 
upper gastrointestinal (Upper GI) and hepato-pancreato-biliary (HPB) surgery (including 
both benign and malignant conditions) via an online survey (http://surveymonkey.com). The 
social media platform Twitter was also used to broaden the awareness of the Delphi process 
amongst interested stakeholders.  There was no limit on the number of research questions 
that an individual could submit. The survey was open submissions for 3 months with three 
email reminders sent to the AUGIS membership during this period. 
 
Submitted questions were collated, anonymised and then grouped into four categories: 1) 
Hepato-Pancreatic and B 2) Benign upper GI 3) Malignant OG and 4) Bariatric and metabolic 
surgery. Any disagreements regarding categorisation were resolved by consensus.  
 
For category (3), an OG cancer surgery steering committee was then formed. Duplicate 
questions were removed. Questions with a similar theme were altered by consensus 




OG cancer surgery research questions were prioritised by AUGIS members by email 
invitation with a link to an online survey (Google forms). Twitter was again used to highlight 
the prioritisation process amongst interested stakeholders. The survey contained all of the 
OG cancer surgery research questions and respondents were asked to prioritise each 
question using a Likert scale (1 – lowest priority to 5 – highest priority). The survey remained 
open to submissions for 16 weeks with three email reminders sent to AUGIS members. The 
results were anonymised and reviewed by the steering committee and a ‘cut-off’ point 
agreed by consensus based on a mean score ≥3.7 following prioritisation for inclusion in the 
final round of prioritisation.  
 
Phase III 
A final round of prioritisation was performed after AUGIS members were again invited by 
email and Twitter to follow a link to a Google forms survey and prioritise the questions using 
the same Likert scale as in Phase II. The survey remained open for 8 weeks and three email 
reminders were sent. Results were anonymised and reviewed by the steering committee to 
identify the final list of prioritised questions. The criteria for inclusion in the final list of 
research priorities was a mean score of ≥3.5, a Likert score of 4-5 by >65.0% respondents 
and a Likert score of 1-2 by <15.0% respondents. 
 
Steering committee 
The OG cancer surgery steering committee consisted of two Upper GI surgical senior 
trainees (NB, MW), two consultant OG cancer surgeons (RV and TU), a consultant oncologist 
(RP) and a lay representative (CB). The overall role of the steering committee was to ensure 
relevance of the submitted questions from both a clinical and patient perspective and to 




In total, 427 research questions were submitted by 140 AUGIS members in Phase I, 
representing 47.6% of the membership (Figure 2). Of those responding, a sub-specialisation 
OG cancer surgery interest was declared by 57 (40.7%). 
Once duplicated and similar questions were reviewed and amended or removed by 
consensus agreement, 75 questions were moved forward for prioritisation in phase II. Fifty-
two stakeholders voluntarily prioritised the questions in phase II. Responses were received 
from 34 consultant surgeons, 12 trainee grade surgeons, 3 dietitians, 1 consultant 
oncologist, 1 UGI nurse specialist and 1 public health research fellow. An analysis of the 
prioritisation was performed by the steering committee and consensus reached regarding a 
cut-off for inclusion (mean ≥3.7) in phase III. 
 
Twenty-one questions were included in the final phase of prioritisation and 46 stakeholders 
took part. Responses were received from 36 consultant surgeons, 7 trainee grade surgeons, 
2 dietitians and 1 consultant anaesthetist. Following review by the steering committee with 
consensus agreement on the criteria for inclusion on the final list of clinical priorities, 12 
questions were included on the final list of OG cancer surgery questions with high research 
priority (Figure 3). Our list of prioritised questions focuses on questions with the following 
themes 
1) Personalised treatment regimens – molecular characterisation with personalised or 
tailored immunotherapies 
2) Identifying those who will not benefit from adjuvant therapies  
3) Optimal palliation – chemotherapy, surgery or best supportive care 
4) Earlier detection of OG cancer  
5) Prehabilitation prior to OG resectional surgery – is it beneficial and what is the 
optimal programme? 
 
The questions which failed to make the final list of research priorities from phase III can be 






This study has produced a list of 12 high priority research questions in the field of OG cancer 
surgery using a modified Delphi process. To our knowledge this is the first time that such a 
project has been undertaken in the field of OG cancer surgery. Previous studies have used a 
Delphi process to develop consensus statements for the management of Barrett’s dysplasia 
and early stage gastric cancer (22), gastric cancer prevention (23) and a core information set 
for oesophageal cancer surgery (21). This study was undertaken as part of a wider project to 
develop the research priorities in the field of Upper GI surgery (also incorporating the 
subspecialty interests of bariatric and metabolic surgery, HPB and benign upper GI surgery). 
 
From our list of prioritised questions there is a significant emphasis on focusing future 
research on tailored or personalised treatments in OG cancer. These include personalised 
chemo/radiotherapy treatments, randomised trials of tailored therapy following the 
molecular characterisation of OG cancers and identifying patients who are the most likely to 
benefit from adjuvant treatments.  Looking to the future a need to further define the role of 
immunotherapy in the management of OG cancer was also identified. 
From phase II of the study a number of questions failed to make the final list of prioritised 
questions. The reasons for failing to make the final list will be multifactorial. However, one 
explanation could be that ongoing research projects will hopefully answer some of the 
proposed questions. An example of this relates to the prevention of anastomotic leaks in OG 
cancer surgery. This question is being addressed in the Oesophagogastric anastomosis audit 
(OGAA) study (26). The outcome of the ROMIO (27) study should also help to determine the 
best predictors of long term survival following oesophagectomy. Some questions may have 
failed to be prioritised sufficiently because they were addressing oesophageal or gastric 
cancer separately. It may have been better to use the term OG cancer consistently (e.g. 
What are the best predictors of long term survival for OG cancer?). This may also explain 
why the optimal palliation question pertaining to oesophageal cancer failed to be prioritised 
but the same question for gastric cancer was sufficiently prioritised. 
 
In the final round of prioritisation, 93.6% respondents were surgeons. This is a limitation of 
our study. A broader range of contributions from across the OG cancer multidisciplinary 
team (oncologists, dietitians, radiologists, specialist nurses, pathologists) may have altered 
the list of highly prioritised questions. Nevertheless, a number of the prioritised questions 
do not specifically relate to the surgical management or outcomes following OG cancer. The 
topics in the final prioritised list range from improving earlier detection of OG cancer to the 
optimal palliative treatment options. Twitter was used to publicise the existence of the 
survey, and therefore the survey was in the public domain and open to submissions from lay 
individuals, patients and family members. Unfortunately, no submissions were received 
from non-healthcare professionals. We did however have lay representation on the steering 
committee (CB). CB was involved in the discussion and agreement upon methodology in 
phase II and III of the study. Reassuringly, the final list of priorities mirrors those in the 
OCCAMS consortium and Oelixir projects (personal communication, TU).  Both are UK-wide 
research initiatives in oesophageal cancer where extensive patient and public engagement 
has been at the core of agenda-setting.   
 
Previous Delphi processes in other specialties reported response rates ranging from 11 to 
25% (15, 17). Our response rate in phase I across all specialties was 47.6% and this should 
therefore be considered as sufficient engagement from the AUGIS membership. The list of 
prioritised research questions will be shared with funding bodies. The expectation is that 
our list of research questions will provide a focus of future research topics and be a useful 
resource for research grant and clinical trial applications. Further, AUGIS members who 
contributed to this study at any point from phase I to II may become motivated to 
undertake future research in to some of the questions identified by this consensus agreed 
Delphi process.  Indeed, this is already being taken forward by the AUGIS/Heartburn Cancer 
UK, Royal College of Surgeons of England Surgical Specialty Lead for Oesophageal Cancer as 
part of the Surgical Trials Initiative. 
 
Conclusion 
In summary, our modified Delphi process has produced a list of questions that have been 
deemed by consensus amongst UK OG cancer specialists to have the highest research 
priority in the field of OG cancer surgery. There is an emphasis on tailored or personalised 
treatment options particularly in relation to the role of immunotherapy in the management 
of OG cancer. Future research projects should seek to address these questions as well as to 
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Figure 1. The modified Delphi process used to prioritise research questions in 












Figure 3 Research priorities for oesophagogastric cancer surgery 
INCLUDED Questions 
Is neoadjuvant chemoradiotherapy better than chemotherapy alone for oesophageal 
adenocarcinoma? 
Is surgery (with neoadjuvant treatment) more effective than optimal non-surgical oncological 
treatment in patients with advanced but non metastatic OG cancer? 
Are personalised chemotherapy treatments possible for OG cancer? 
Is there a role for tailored chemo/radiotherapy for OG cancer? 
Why do some patients fail to respond to chemotherapy for OG cancer? 
What is the best way to identify patients with OG cancer who will not benefit from peri-
operative chemotherapy? 
Should we support the molecular characterisation of OG cancers and randomised trials of 
tailored therapy? 
How can we improve the identification of patients who are most likely to benefit from 
adjuvant treatment for resectable OG cancer? 
What is the role of immunotherapy or other novel therapies in the treatment of OG cancer? 
What palliative treatment provides the best quality of life in irresectable gastric cancer; 
chemotherapy, surgery or best supportive care? 
How can we detect OG cancer earlier? 




Click here to download Supplementary Material: Appendix 1 OG cancer.docx
